Neuromodulation is a technology that directly affects nerves. It is the modification—or modulation—of nerve function by delivering electrical or pharmaceutical agents directly to a target site. Neuromodulation treatments and devices can be life altering. They impact all regions of the body and address almost every disease or symptom ranging from headaches to tremors to spinal cord injury to urinary incontinence. With such a wide therapeutic range, and with dramatic continuing advances in biotechnology, it is no wonder that neuromodulation is a prime growth industry for the coming decade.
They tend to associate most often with relief of chronic pain, the most prevalent indication. But there is a wide array of neuromodulation applications, including DBS therapy for Parkinson’s disease, sacral nerve stimulation for pelvic disease and incontinence, and spinal cord stimulation for ischemic conditions (angina, peripheral vascular disease). Moreover, neuromodulation devices are capable of eliciting a response where none existed before, such as in the instance of a cochlear implant restoring hearing in a deaf patient.
The market for neuromodulation devices was valued at USD 6.1 billion in 2024 and is anticipated to grow at a CAGR of 9.7% during the forecast period. Major factors that drive the growth of the market are increasing prevalence of chronic pain, neurological disorders and mental health conditions.
According to the CDC Centers for Disease Control and Prevention, in the year 2023, it was reported that 24.3% of the adult population suffered from chronic pain, while 8.5% faced high-impact chronic pain, which corresponds to 34.9% of those individuals living with chronic pain. The data also indicated a higher prevalence of chronic pain among women compared to men, highlighting a significant gender disparity in the experience of this condition.
Such prevalence of chronic pain indicated the rising demand for effective treatment option. This increases the demand for neuromodulation procedures and thus increases the demand for neuromodulation devices. In addition, advancements in the technologies and development of minimally invasive neuromodulation devices further leads to the expansion of the market.
Pioneering Research and Innovations in Neuromodulation Devices
The neuromodulation business is seeing next-generation R&D innovations in non-invasive and implantable devices. Researchers are working on new-generation Deep Brain Stimulation (DBS), Vagus nerve stimulation (VNS), and Spinal Cord Stimulation (SCS) to bring better patient results.
Some such advancements are:
· Closed-loop systems of neuromodulation, which respond adaptively in real time to patients’ responses for optimizing therapy specificity.
· Wireless and battery-independent neuromodulation implants for minimizing replacement operations and lowering risks of surgery.
· AI-based devices with the ability to interpret neurological patterns and regulate levels of stimulation on their own.
· Bioelectronic medicine, combining neuromodulation with drug delivery systems to maximize therapeutic impacts.
Major organizations like Harvard University, Mayo Clinic, and Stanford University are all aggressively pursuing new applications, including neuromodulation for psychiatric illnesses, cognitive enhancement, and rehabilitation treatments for stroke victims.
Regional Adoption: The Global Expansion of Neuromodulation Technologies.
The regions of the United States, Europe, and Asia-Pacific are currently recognized as the most significant and rapidly expanding markets for neuromodulation technologies. In North America, the United States stands out as the leader in the neuromodulation devices sector, primarily due to its robust healthcare infrastructure and favorable reimbursement policies. The high incidence of chronic pain and neurological disorders further contributes to this dominance, alongside the presence of major manufacturers in the field, including Medtronic, Abbott, and Boston Scientific.
In Europe, countries such as Germany, France, and the United Kingdom are experiencing substantial growth, driven by government-funded research initiatives focused on brain stimulation therapies. This growth is also supported by the increasing applications of neuromodulation in neuropsychiatric and pain management treatments, as well as significant advancements in wireless and AI-enhanced neuromodulation systems.
Meanwhile, the Asia-Pacific region is anticipated to witness the most rapid growth, propelled by the rising elderly populations in nations like Japan and China, which heightens the demand for treatments related to Parkinson’s and Alzheimer’s diseases. Additionally, there is a growing awareness and acceptance of neuromodulation therapies, coupled with improvements in healthcare access and infrastructure in countries such as India, China, and South Korea.
Investment and Funding: The Financial Push Accelerating Neuromodulation Growth
The market for neuromodulation devices is witnessing an upsurge in investments and funding due to the growing need for new treatments for neurological disorders and managing chronic pain. Venture capital, government, and private investors are increasingly supporting neuromodulation startups and incumbent companies to drive R&D, clinical trials, and commercialization of next-generation neurostimulation technologies.
Over the past couple of years, a few high-profile funding rounds have been reported, which underline robust investor trust in the industry.
For instance, in August 2020, NeuroPace Inc., a company at the forefront of responsive neurostimulation (RNS) for epilepsy, raised $67 million in a round to increase its device family and increase real-time monitoring capabilities.
Likewise, in January 2025, Saluda Medical, Inc., a company engaged in the commercial development of medical devices, has announced the successful completion of a $100 million financing round. This organization is dedicated to creating innovative treatments for chronic neurological disorders through its unique closed-loop, dose-control neuromodulation technology.
Government institutions are also taking a leading role in financing neuromodulation research. The European Commission’s Horizon 2020 initiative has also provided millions to develop bioelectronic medicine and AI-based neuromodulation.
With more mergers, acquisitions, and strategic alliances, industry titans such as Medtronic, Abbott, and Boston Scientific are buying potential startups to merge innovative technology with their product portfolios. These financial injections are set to fuel market growth, making treatment cheaper and more accessible for patients globally.
Key Developments Shaping the Neuromodulation Devices Market
· In December 2024, Wavegate has secured $26 million in funding aimed at advancing its neuromodulation technology designed for the management of chronic pain. The financial resources will be allocated to expedite the development of the Ellipse Spinal Cord Stimulator Platform, which is specifically engineered to provide therapeutic solutions for individuals suffering from persistent pain conditions.
· In June 2024, PathMaker Neurosystems, a company specializing in euromodulation, has successfully obtained $2.16 million in funding from the United States Department of Defense (DoD) to support a clinical trial. This trial will utilize the MyoRegulator, an investigational device developed by the company, aimed at treating individuals diagnosed with amyotrophic lateral sclerosis (ALS).
· In April 2024, the SAINT Neuromodulation device, a ground-breaking, fast-acting treatment for treatment-resistant major depressive disorder (MDD), has been commercialized by Magnus Medical, Inc., a pioneering therapeutic neuromodulation business revolutionizing the treatment of neuropsychiatric illnesses.
· In November 2024, Medtronic has introduced the FDA-approved InterStim X sacral nerve stimulation therapy in India, aimed at addressing bladder and bowel control challenges. This innovative approach, known as sacral neuromodulation, offers a sophisticated treatment option for individuals experiencing difficulties with bladder and bowel management, particularly when conventional therapies have proven ineffective.
About Author:
HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.
